Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Shares of Novavax Inc. NVAX, +14.32% jumped 11.9% in trading on Tuesday after the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices voted in favor of the company's COVID-19 vaccine. The next step is for CDC director Rochelle Walensky to decide whether to sign off on the decision; if she does, the vaccine will then be made available to adults in the U.S. The Food and Drug Administration granted emergency authorization to the two-dose, protein vaccine last week.

CDC committee recommends Novavax's COVID-19 vaccine

The recommendation from the CDC's Advisory Committee on Immunization Practices heads to CDC director Rochelle Walensky for approval.

CDC Advisors Recommend Novavax Covid Vaccine For Adults

Novavax has several catalysts igniting NVAX stock higher today. The bulls hope this is just the beginning for NVAX shares.

2 Big Reasons Novavax (NVAX) Stock Is Shooting Higher Today

Novavax uses different technology than Pfizer and Moderna. U.S. health officials hope Novavax's shots might convince skeptics to get vaccinated.

CDC panel unanimously recommends Novavax Covid-19 vaccine for adults

Novavax Inc (NASDAQ: NVAX) shares are trading higher Tuesday as CDC advisers meet to discuss the company's COVID-19 vaccine. Novavax also announced agreements with SK bioscience for the manufacturing and supply of a version of the vaccine containing the Omicron variant.

Why Novavax Stock Is Surging Today

GAITHERSBURG, Md. , July 19, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, has signed agreements with its partner, SK bioscience, for the manufacturing and supply of a version of the Novavax COVID-19 vaccine (NVX-CoV2373) containing Omicron variant and for the manufacture of the vaccine in prefilled syringes.

Novavax Announces Expanded Agreement with SK bioscience to Manufacture COVID-19 Vaccine Containing Omicron Variant and Manufacture the Novavax COVID-19 Vaccine in Prefilled Syringes

Vaccine developer Novavax (NASDAQ: NVAX) stock has collapsed (-61%) in 2022. The Company's protein-based COVID-19 vaccine Nuvaxovid has launched in Europe and awaits CDC approval for launch the U.S.

Is it Time to Cash Out Novavax Stock?

Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Novavax (NVAX) Soars 5.4%: Is Further Upside Left in the Stock?

Carvana

Shopify

Velo3D

Some stocks have been really hammered, and are down 70%, 80%, or even 90% off their highs. If you want to buy a stock in that scenario, how should you approach it?

2 Ways to Fish at the Bottom of the Market

The shares are down -- but revenue and profit are on the rise.

After a 26% Drop, Should You Give Up on Novavax?

Green Thumb Industries Inc.

Upstart Holdings

These supercharged growth stocks have the tools and intangibles necessary to make patient investors a lot richer.

3 Monster Growth Stocks That Can Turn $350,000 Into $1 Million by 2028

The FDA has authorized a new COVID vaccine, and the CDC will decide soon how it'll roll out. Here's what to know.

What You Should Know About Novavax

Novavax finally secured its EUA from the FDA this week. Its COVID vaccine becomes the fourth authorized in the US.

Novavax: EUA Win A Cause To Celebrate Despite Anaphylaxis Warning

Novavax (NVAX) stock is in the spotlight on Friday as investors react to recent FDA news concerning its Covid-19 vaccine. The post Is Novavax (NVAX) Stock a Buy After FDA Decision?

Is Novavax (NVAX) Stock a Buy After FDA Decision?

FDA finally granted Emergency Use Authorization to Novavax's Covid-19 vaccine. The classic sell-the-news scenario paired with an overseas label change might have created the perfect entrance point for Novavax.

10 Reasons To Buy The Novavax Slaughterfest

The administration of Novavax's (NVAX) COVID-19 vaccine leads to some cases of severe allergic reactions as well as skin problems, per a safety update issued by the EMA.

Novavax (NVAX) Down as EU Adds Side Effects to COVID Jab Label

Stocks usually soar on good news. But there were some complicating factors for Novavax.

Novavax's Vaccine Won U.S. Authorization: 5 Reasons Why Its Stock Still Crashed

Following the grant of emergency use authorization by the FDA, Novavax's (NVAX) COVID-19 vaccine is the first protein-based COVID vaccine authorized for use in the United States.

Novavax's (NVAX) Protein-Based COVID Jab Gets EUA in the US

U.S. health regulators authorized the use of Novavax Inc.'s COVID-19 vaccine, providing a new option that works differently than the two leading vaccines based on mRNA technology, but the move comes at a time when uptake of shots and boosters is low.

Novavax's protein-based vaccine approval fails to boost stock as demand for shots and boosters remains low

The move comes as the contagious BA.5 subvariant takes hold in the US.

FDA Authorizes New COVID Vaccine, From Novavax

Officials hope the protein-based vaccine will appeal to the nearly 22% of Americans who have not received a single dose of a Covid-19 inoculation.

FDA Authorizes Novavax's Covid-19 Vaccine For Adults

Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S. Immunizations with the Novavax COVID-19 Vaccine, Adjuvanted as a primary series will begin upon product release and once a policy recommendation from the CDC is received GAITHERSBURG, Md. , July 13, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to provide a two-dose primary series for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and over.

U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over

The FDA says Novavax gives Americans “another option" to the three vaccines already authorized at a time when interest in vaccines is waning.

FDA Clears Novavax as a Covid-19 Vaccine

U.S. health regulators have authorized the use of Novavax Inc.'s COVID-19 vaccine, providing a new option that works differently than the two leading vaccines, but at a time when overall demand for vaccines and boosters is low.

FDA approves Novavax's COVID-19 vaccine for those 18 and older

FDA authorization of Novavax's vaccine was delayed for weeks as the agency reviewed changes to the company's manufacturing process.

News for Novavax Stock (NVAX)